Targeting a specific process in pancreatic cancer to improve treatment outcomes
Macropinocytosis Inhibition as a Glutamine Mimetic Sensitization Strategy in Pancreatic Cancer
['FUNDING_R01'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-10990805
This study is looking at how pancreatic cancer cells use a nutrient called glutamine and how blocking a specific process can make a treatment called DON work better, with the goal of finding new ways to help patients with pancreatic cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10990805 on ClinicalTrials.gov |
What this research studies
This research investigates how pancreatic cancer cells utilize glutamine and how inhibiting a process called macropinocytosis can enhance the effectiveness of a treatment using a compound known as DON. The study aims to understand the metabolic adaptations of cancer cells and how blocking certain pathways can make tumors more susceptible to therapy. By exploring the relationship between glutamine and asparagine in cancer cell survival, the researchers hope to develop a new strategy to combat pancreatic cancer. Patients may be involved in trials that test this innovative approach to treatment.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While targeting metabolic pathways in cancer is a growing field, this specific approach of inhibiting macropinocytosis in pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COMMISSO, COSIMO — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: COMMISSO, COSIMO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.